The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505.

ConditionErectile Dysfunctions

Trial statusNot yet recruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexMale

Age19+

SponsorGL Pharm Tech Corporation

About this trial

The purpose of this study is to evaluate the efficacy and safety of W2505.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male aged 19 years or older.

Capable of completing study diaries and questionnaires independently.

Signed written informed consent.

run-in medication compliance ≥ 70%

Disqualifiers

Primary hypoactive sexual desire.

Erectile dysfunction caused by premature ejaculation or untreated endocrine disorders (e.g., untreated hypogonadism, hyperprolactinemia).

Other exclusions applied.

Trial design

Design model

Parallel

Treatments tested in this trial

W2505
Drug
PO, Once daily(QD), 12 weeks
W2505-P1
Drug
PO, Once daily(QD), 12 weeks
W2505-R
Drug
PO, Once daily(QD), 12 weeks
W2505-P2
Drug
PO, Once daily(QD), 12 weeks

Treatment groups

228 Participants

are divided into 3 treatment groups

Group A: ExperimentalExperimental treatment 2 interventions

Group B: Placebo ComparatorPlacebo comparator 2 interventions

Group C: Active ComparatorActive comparator 2 interventions

Trial outcomes

Primary outcomes

Change from Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score

Change from baseline in the erectile function domain score assessed using the International Index of Erectile Function (IIEF) questionnaire.

Time frame

Baseline, Week 12

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

GL Pharm Tech Corporation

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: